Potential Breakthrough in Encapsulation Technology

JDRF-funded researchers develop novel method of protecting islets for implantation into people with type 1 diabetes Pancreatic islet transplantation has restored insulin independence in some individuals with type 1 diabetes (T1D), but the procedure is not widely available due to the limited supply of donated islets and the need for strong immunosuppressive drugs to prevent […]

Cocktail Immune Therapy Beats Going Solo

New clinical results show positive effect of combination immune therapy for type 1 diabetes Type 1 diabetes (T1D) is caused when the immune system mistakenly attacks insulin-producing beta cells within the pancreas. While there have been numerous clinical studies using general immunotherapy to stop or slow the T1D attack, researchers have been generally disappointed with […]

Changing the Standard Management of Type 1 Diabetes

Adding novel therapy to an insulin regimen may allow for better glucose control and reduced insulin dosages Before insulin was discovered in 1921, people with type 1 diabetes (T1D) didn’t live very long. Its discovery was a great breakthrough and saved lives, but since then the basic management of T1D has continued to remain focused […]

A Difficult Journey from the Lab to People with Type 1 Diabetes

New study highlights the challenges of translating promising research to effective treatments Results from a clinical study in people with type 1 diabetes (T1D) who were treated with a combination of two drugs in an attempt to improve their beta cell survival and stimulate beta cell regeneration are so far inconclusive. The study, called REPAIR-T1D […]

Top 10 Advances in T1D Research

JDRF-supported progress in fiscal year 2014 JDRF sets ambitious goals for progress in type 1 diabetes (T1D) research each year because our supporters inspire us to aim higher. We invite you to read about the real impact our strategic plan is making and hope you are as inspired as we are as each of these […]

Next-Generation Artificial Pancreas System Gears Up for Test Drive

Pilot study will evaluate advanced artificial pancreas technology under real-world situations For several years, JDRF-funded researchers at the University of Virginia Center for Diabetes Technology have been hard at work designing an artificial pancreas system that would allow individuals with type 1 diabetes (T1D) to go about their daily lives and sleep through the night […]

JDRF Ranked as Top Non-Governmental Diabetes Research Funder

Independent analysis of key scientific literature found JDRF among the top organizations funding diabetes research globally In a recent independent analysis of key diabetes-related scientific literature, JDRF was ranked as the third most frequently cited funder of diabetes research globally, behind only the U.S. National Institutes of Health and the National Natural Science Foundation of […]

A Picture’s Worth a Thousand Words

JDRF-Funded Study Shows New Imaging Technique Can Track Beta Cell Status For nearly 100 years, we have known that type 1 diabetes (T1D) is a disease fundamentally about the progressive loss of insulin-producing beta cells, but measuring that loss has continued to elude researchers—at least until now. In a recent scientific publication, JDRF-funded researchers used […]

Specific Protein May Help Beta Cells Survive in Type 1 Diabetes

JDRF-funded researchers find therapeutic potential of MANF protein to reduce beta cell stress in type 1 diabetes. In the healthy pancreas of someone without type 1 diabetes (T1D), the hormone insulin (essential for turning food into energy) is produced, stored, and released in a normal “factory-like” process within pancreatic beta cells in response to glucose […]

Sleeping Without Fear

Study: Artificial pancreas systems with predictive low-glucose-suspend help reduce overnight hypoglycemia in individuals with type 1 diabetes Bedtime may soon be safer and a lot less anxiety filled for people with type 1 diabetes (T1D) thanks to software being developed as a next-step component for artificial pancreas systems. Called predictive low-glucose-suspend (pLGS), it interacts with […]